医薬品製造アウトソーシングにおける主要企業：市場開発、アウトソーシング・ホットスポット、成長戦略

未登録の方はこちらから登録できます。

会員規約

TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com

市場調査のご依頼、専門分野のイベント・フォーラムの開催などはシード・プランニングにて承っております。

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。

Key Players in Pharmaceutical Contract Manufacturing: Market developments, outsourcing hotspots and growth strategies

医薬品製造アウトソーシングにおける主要企業：市場開発、アウトソーシング・ホットスポット、成長戦略

医薬品受託製造企業はコスト圧力、厳しい規制条件、特許失効などに後押しされて着実に成長を続けています。この産業は元来激しい競争環境にあるため統合が進んでおり、企業はコスト削減のため海外の新興市場に製造を委託する傾向が強くなっています。その結果、主要な製造受託企業は製造インフラを改善して世界的な競争力を高めようとしています。

このレポートは世界の医薬品製造受託産業の競争環境について詳細な調査、分析を行い、この市場における最新の主要課題、動向を深く掘り下げます。CMO上位10社について、事業セグメント別業績、製造および研究開発能力、成長戦略、主な買収・売却などを詳細に分析します。また、世界のCMO産業の規模と伸び率、市場動向の分析も行います。

Executive summary: Market development
Catalent
Lonza
Boehringer Ingelheim (BI)
DSM
Evonik
Patheon
Piramal
Jubilant
Aenova
Fareva
Chapter 1 Introduction: What is this report about?
Methodology
Chapter 2 Market development: Summary
Overview
Market size and growth
Positioning and performance of leading players
Drivers of manufacturing outsourcing
Key trends in the market

Increasing offshore outsourcing by Big Pharma
Expansion of biopharmaceutical contract manufacturing
Industry consolidation
Contract manufacturing hotspots . India and China
India

Contract manufacturing in India
Key CMOs in India

China

Contract Manufacturing in China
Key CMOs in China

Comparison of India and China on key parameters

Availability of skilled labor
Cost
Manufacturing infrastructure
Global capabilities
Service portfolio

Concerns about offshoring
Chapter 3 Catalent: Summary
Company overview
Group structure
Oral Technologies
Sterile Technologies
Packaging Services
Recent financial performance
Performance by business segments

Oral Technologies
Sterile Technologies
Packaging Services

Performance by geographies
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Chapter 4 Lonza: Summary
Company overview
Group structure
Life Science Ingredients
Exclusive Synthesis & Biopharmaceuticals
Bioscience
Recent financial performance
Performance by business segments
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Capacity expansion
Strategic partnerships and acquisitions
High value products
Chapter 5 Boehringer Ingelheim (BI): Summary
Company overview
Group structure
Biopharmaceuticals
Pharmaceuticals Production
Pharma Chemicals
Recent financial performance
Performance by business segments
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Capacity expansion
Strategic partnerships
Chapter 6 Royal DSM (DSM): Summary
Company overview
Group structure
Recent financial performance
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Chapter 7 Evonik (Degussa): Summary
Company overview
Group structure
Recent financial performance
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Restructuring of operations
Geographic restructuring
Capacity expansion
Geographic expansion
Chapter 8 Patheon: Summary
Company overview
Group structure
Commercial Manufacturing
Pharmaceutical Development Services (PDS)
Recent financial performance
Performance by business segments
Performance by geographies
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Focus on prescription drugs business
Improve profitability and capacity utilization
Diversify customer base
Chapter 9 Piramal Healthcare (Piramal): Summary
Company overview
Group structure
PDS (Pharmaceutical Development Services)
PMS (Pharmaceutical Manufacturing Services)
MMBB (Manufacturing Molecules/ Building Blocks)
Others
Recent financial performance
Performance by business segments
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Chapter 10 Jubilant Organosys (Jubilant): Summary
Company overview
Group structure
Recent financial performance
Performance by product segments
Performance by geographies
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Chapter 11 Aenova: Summary
Company overview
Group structure
Swiss Caps
Dragenopharm
Recent financial performance
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Chapter 12 Fareva: Summary
Company overview
Group structure
Recent financial performance
Manufacturing and R&D
Acquisitions and divestments
Growth strategies
Chapter 13 11 to 20 Companies: Nipro
Company overview
Recent financial performance
Siegfried
Company description
Recent financial performance
Haupt
Company description
Recent financial performance
Divi's Laboratories (Divi's)
Company description
Recent financial performance
Cambrex
Company description
Recent financial performance
Recipharm
Company description
Recent financial performance
Archimica
Company description
Vetter
Company description
Famar
Company description
NextPharma
Company description
Other contract manufacturers
Index
List of Figures: Figure 2.1: Global pharmaceutical contract manufacturing market size, 2007-2011
Figure 2.2: Positioning of leading players (2007)*
Figure 2.3: Labor cost in select countries
Figure 2.4: No. of FDA approved plants outside the US, 2007
Figure 3.5: Catalent's financial performance ($m), 2004-2008*
Figure 3.6: Catalent's revenue break-up by geography (%), 2008
Figure 4.7: Lonza's contract manufacturing financial performance ($m), 2005-2007*
Figure 5.8: BI Industrial Customers' financial performance ($m), 2005-2007*
Figure 6.9: DSM DPP's financial performance ($m), 2005-2007*
Figure 7.10: Evonik's Health & Nutrition financial performance ($m), 2006-2007*
Figure 8.11: Patheon's financial performance ($m), 2006-2008*
Figure 8.12: Patheon's Commercial Manufacturing revenue break-up by geography (%), 2008*
Figure 9.13: Piramal Pharma Solutions' financial performance ($m), 2006-2007*
Figure 10.14: Jubilant's CRAMS financial performance ($m), 2003-2007*
Figure 10.15: Jubilant's revenue break-up by geography (%), 2007*
Figure 12.16: Fareva Pharmaceuticals' financial performance ($m), 2006-2008*
List of Tables: Table 2.1: Leading pharmaceutical contract manufacturing companies, 2007
Table 2.2: Select manufacturing outsourcing initiatives planned by the Big Pharma
Table 2.3: Leading CMOs in India
Table 2.4: Select foreign acquisitions by Indian players
Table 2.5: Manufacturing cost comparison
Table 3.6: Catalent's snapshot
Table 3.7: Catalent's financial performance ($m), 2004-2008
Table 3.8: Catalent's business segments performance ($m), 2006-2008
Table 3.9: Catalent's performance by geography ($m), 2006.2008
Table 4.10: Lonza's snapshot
Table 4.11: Lonza's contract manufacturing financial performance ($m), 2005-2007
Table 4.12: Lonza's contract manufacturing business segments performance ($m), 2005-2007
Table 5.13: BI's snapshot
Table 5.14: BI Industrial Customers' financial performance ($m), 2005-2007
Table 5.15: BI Industrial Customers' business segments performance ($m), 2005-2007
Table 6.16: DSM's snapshot
Table 6.17: DSM DPP's financial performance ($m), 2005-2007
Table 7.18: Evonik's snapshot
Table 7.19: Evonik's Health & Nutrition financial performance ($m), 2006-2007
Table 8.20: Patheon's snapshot
Table 8.21: Patheon's financial performance ($m), 2006-2008
Table 8.22: Patheon's business segments performance ($m), 2008
Table 8.23: Patheon's Commercial Manufacturing performance by geography ($m), 2007.2008
Table 9.24: Piramal's snapshot
Table 9.25: Piramal Pharma Solutions' financial performance ($m), 2006-2007
Table 9.26: Piramal Pharma Solutions' business segments performance ($m), 2005-2007
Table 10.27: Jubilant's snapshot
Table 10.28: Jubilant's CRAMS financial performance ($m), 2003-2007
Table 10.29: Jubilant's CRAMS product segments performance ($m), 2006-2007
Table 10.30: Jubilant's performance by geography ($m), 2005.2007
Table 11.31: Aenova's snapshot
Table 12.32: Fareva's snapshot
Table 12.33: Fareva Pharmaceuticals' financial performance ($m), 2006-2008
Table 13.34: Nipro's snapshot
Table 13.35: Nipro's Pharmaceutical financial performance ($m), 2003-2007 *
Table 13.36: Siegfried's snapshot
Table 13.37: Siegfried's financial performance ($m), 2006-2007*
Table 13.38: Haupt's snapshot
Table 13.39: Divi's' snapshot
Table 13.40: Divi's financial performance ($m), 2003-2007
Table 13.41: Cambrex's snapshot
Table 13.42: Cambrex's financial performance ($m), 2005-2007*
Table 13.43: Recipharm's snapshot
Table 13.44: Recipharm's financial performance ($m), 2003-2008
Table 13.45: Archimica's snapshot
Table 13.46: Vetter's snapshot
Table 13.47: Famar's snapshot
Table 13.48: NextPharma's snapshot
Table 13.49: Other select contract manufacturers

発刊日

2009/04/01

体裁

PDF / 143ページ

販売価格

3,835USD

発行

Business Insights Ltd.

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

SPI Infoamtion

医薬品製造アウトソーシングにおける主要企業：市場開発、アウトソーシング・ホットスポット、成長戦略

目次

発刊日

体裁

販売価格

発行

備考

関連カテゴリ

購入・お問い合わせ